1. Верткин А.Л., Ткачева О.Н., Подпругина Н.Г. и др.  Диабетическая автономная нейропатия: диагностика и метаболическая нейропатия. Клин. фармакол. и тер. 2004; 4: 4–8.
2. Левин О.С. Полиневропатия. М.: МИА, 2006.
3. Строков И.А., Баринов А.Н. Клиника, патогенез и лечение болевого синдрома при диабетической полиневропатии. Неврологич. журн. 2001; 6: 47–54.
4. Штульман Д.Р., Левин О.С. Неврология. Справочник практического врача. М.: МЕДпресс-информ, 2008.
5. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2009; 32 (Suppl. 1): S62–7.
6. Ametov AS, Barinov A, Dyck PJ et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha-lipoic acid. Diabetes Care 2003; 26: 770–6.
7. Bitsch R, Wolf M, Moller J et al. Bioavailability assessment of the lipophilic benfothiamine as compared to a water-solubile thiamin derivate. Ann Nutr Metab 1991; 35: 292–6.
8. Boulton AJ, Vinik AI, Arezzo JC et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care 2005; 28 (4): 956–62.
9. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518–22.
10. DCCT Research Group. The effect of intensive diabetes therapy on the development and progression of neuropathy. Ann Intern Med 1995; 122: 561–8.
11. Dyck PJ, Karnes JL, O’Brien PC et al. The Rochester Diabetic Neuropathy study: reassessment of tests and criteria for diagnosis and staged severity. Neurology 1992; 42: 1164–70.
12. Dyck PJ, Kratz KM, Karnes JL et al. The prevalence by staged severity of various types of diabetic neuropathy, retinopathy and nephropathy in a population-based cohort: The Rochester Diabetic Neuropathy study. Neurology 1993; 43: 817–24.
13. Dyck PJ, Thomas PK (eds). Diabetic neuropathy. 2d ed. Philadelphia: WB Saunders, 1999.
14. Dyck PJB. Diabetic Radiculoplexus Neuropathies. In: JH.Noseworthy (ed.). Neurological therapeutics:principles and practice. Martin Dunitz, 2003; p. 2007–10.
15. Gries FA, Cameron NE, Low PA (eds). Textbook of Diabetic Neuropathy. Stuttgart: Thieme, 2003.
16. Haak E, Usadel KH, Kusterer K et al. Effects of alpha-lipoic acid on microcirculation in patients with peripheral diabetic neuropathy. Exp Clin Endocrinol Diabetes 2000; 108: 168–74.
17. Heidrich H, Quendnau J, Schirop T. Response of blood sugar and serum insulin to intravenous long-term treatment with actovegin. Clinical double-blind study. Med Klin 1979; 74: 242–5.
18. Herrmann WM, Bohn-Olszewsky WJ, Kuntz G. Infusionstherapie mit Actovegin bei Patienten mit prim?rer degenerativer Demenz vom Alzheimer-Type und Multiinfarkt-Demenz. Z Geriatrie 1992; 5: 46–55.
19. Jacob S, Dietze GJ, Machicao F et al. Improvement of glucose metabolism in patients with type II diabetes after treatment with a hemodialysate. Arzneimittelforschung 1996; 46: 269–72.
20. Jacob S, Henriksen EJ, Tischler HJ et al. Improvement of insulin-simulated glucose disposal in type 2 diabetes after repeated parenteral administration of thioctoc acid. Exp Clin Endocrinol Diabetes 1996; 104: 284–8.
21. Jansen W, Beck E. Treatment of diabetic polyneuropathy. A controlled double blind study. Die Medizinische Welt 1987; 38: 838–41.
22. Kanowski S, Kinzler E, Lehmann E et al. Confirmed clinical efficacy of Actovegin in elderly patients with organic brain syndrome. Pharmacopsychiat 1995; 28: 125–33.
23. Kramer H, Rolke R, Hecht M et al. Follow-up of advanced diabetic neuropathy. J Neurol 2005; p. 315–20.
24. Low PA, Benrud-Larsen LM, Sletten DM et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27: 2942–7.
25. Poremba M, Krott H. Clinical and electrophysiological findings in association with treatment of diabetic polyneuropathy with a protein-free haemodialysate. Metabolische und endzuendlice polyneuropatien. Berlin, Eidelberg, 1984; p. 289–92.
26. Said G, Baudoin D, Toyooka K. Sensory loss, pains, motor deficit and axonal regeneration in length-dependent diabetic polyneuropathy. J Neurol 2008; 255: 1693–702.
27. Stracke H, Linemann A, Federlin K. A benfotiamine-vitamin B combination in treatment of diabetic polyneuropathy. Exp Clin Endocrinol Diabetes 1996; 104: 311–6.
28. Sumner CJ, Sheth S, Griffin JW et al. The spectrum of neuropathy in diabetes and impaired glucose tolerance. Neurology 2003; 60: 108–11.
29. Tesfaye S, Stevens LK, Stephenson JM et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996; 39: 1377–84.
30. Trence DL. Peripheral neuropathy in diabetes: is it diabetic neuropathy? Clin Diabet 2002; 20: 103–4.
31. Vinik AI, Maser RE, Mitchell BD et al. Diabetic autonomic neuropathy. Diabetes Care 2003; 26: 53–81.
32. Vinik AI, Mehrabyan A. Diabetic neuropathies. Med Clin North Am 2004; 88: 947–99.
33. Ziegler D et al. ALADIN Study Group: Treatment of symptomatic diabetic peripheral neuropathy with the anti-oxidant a-lipoic acid (ALADIN Study). Diabetologia 1995; 38: 1425–33.
34. Ziegler D. Treatment of diabetic neuropathy and neuropathic pain. Diabetes Care 2008; 31: 255–61.
35. Ziegler D, Hanefeld M, Ruhnau RJ et al. The ALADIN III Study group. Treatment of symptomatic diabetic peripherial neuropathy with antioxidant alpha-lipoic acid. Diabetes Care 1999; 22: 1296–301.
36. Ziegler D, Movsesyan L, Mankovsky B et al. Treatment with Actovegin in Type 2 Diabetic Patients with Symptomatic Polyneuropathy. Diabetes Care 2009; 10.2337/dc09-0545.

О.С.Левин